Angioedema, use of ACE inhibitors, and SARS-CoV-2 infection

Authors

  • Tamara Gómez-Traveso Servicio de Medicina Interna, Hospital Comarcal de Laredo, Laredo (Cantabria), Spain
  • Raquel Jaso-Tejera Servicio de Medicina Interna, Hospital Comarcal de Laredo, Laredo (Cantabria), Spain
  • Ana González-Torre-González Servicio de Medicina Interna, Hospital Comarcal de Laredo, Laredo (Cantabria), Spain
  • Elena Casuso-Sáenz Servicio de Medicina Interna, Hospital Comarcal de Laredo, Laredo (Cantabria), Spain
  • Nuria Díez-Herrán Servicio de Medicina Interna, Hospital Comarcal de Laredo, Laredo (Cantabria), Spain

DOI:

https://doi.org/10.32818/reccmi.a6n1a4

Keywords:

angioedema, ACE inhibitors, bradykinin, SARS-CoV-2 infection.

Abstract

The SARS-CoV-2 infection, as well as other viral infections, can lead to a considerable variety of cutaneous manifestations. However, angioedema is not usual, generally showing up associated with urticaria and respiratory symptoms. Its emergence in patients who are under ACE inhibitors is not common. It seems that the mechanism by which the virus and ACE inhibitors produce angioedema is similar, both causing dysregulation of ACE-2 receptors and increasing bradykinin levels. It is reasonable to believe that SARS-CoV-2 may act as a potential trigger when combined with the use of these products.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, Navarro Fernández I et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183(1): 71-77. doi: ttps://doi.org/10.1111/bjd.19163.

Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020; 13(7): e236981. doi: https://doi.org/10.1136/bcr-2020-236981.

Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020; 6(10): 1091-1094. doi: https://doi.org/10.1016/j.jdcr.2020.07.042.

Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute urticaria with angioedema in the setting of coronavirus disease 2019. J Allergy Clin Immunol Pract. 2020; 8(7): 2386-2387. doi: https://doi.org/10.1016/j.jaip.2020.04.061.

Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and COVID-19. BMJ Case Rep. 2020 Sep 9;13(9):e237888. doi: https://doi.org/10.1136/bcr-2020-237888.

Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID-19. Eur Heart J. 2020; 41(34): 3283-3284. doi: https://doi.org/10.1093/eurheartj/ehaa452.

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1): 8. doi: https://doi.org/10.1038/s41368-020-0074-x.

Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012; 110(3): 383-91. doi: https://doi.org/10.1016/j.amjcard.2012.03.034.

Published

2021-04-30

How to Cite

1.
Gómez-Traveso T, Jaso-Tejera R, González-Torre-González A, Casuso-Sáenz E, Díez-Herrán N. Angioedema, use of ACE inhibitors, and SARS-CoV-2 infection. Rev Esp Casos Clin Med Intern [Internet]. 2021 Apr. 30 [cited 2024 Nov. 23];6(1):10-2. Available from: https://www.reccmi.com/RECCMI/article/view/597

Most read articles by the same author(s)